Welcome to the Boehringer Ingelheim Pharmaceutical Inc (BIPI) and Lilly USA, LLC (Lilly) Alliance on-line application and grant management portal.

      On January 11, 2011 BIPI and Lilly announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.

      By agreement between BIPI and Lilly, grant requests will be processed through the BIPI on-line grant system but the application request will be reviewed by both companies. The following steps are required in order to process your grant request through our on-line grant management portal:

      Medical Education Grants

      A BIPI/Lilly medical education grant is designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.

      Please see below for submission timelines:

      • Grant applications with total program costs/expenses of $25,000.00 or less, must be submitted no less than 60 days prior to the program start date.
      • Grant applications with total program costs/expenses greater than $25,000.00, must be submitted no less than 90 days prior to the program start date.

      New and Returning Visitors to BIPI/Lilly Medical Grants

      To begin a new application, return to a saved application, or track the status of an application already submitted login at https://bipisupport.envisionpharma.com/vt_bi/. If this is the first time you are visiting the site, you must register as a New User. An application ID beginning with "ME", will be assigned once you submit the application.

      Educational Objectives

      • Discuss the mechanisms of action and clinical data related to incretin based therapies or insulin independent treatment concepts.
      • Outline the morbidity, mortality and cost burdens that result from inadequate management of T2DM in diverse populations (race, ethnicity, gender and age etc).
      • Describe the role of individualized, multifaceted approaches to improving outcomes in relation to diabetes-related health issues including microvascular and/or macrovascular complications.
      • Improve awareness of the importance of early recognition, clinical detection, and diagnosis of renal compromise and appropriate glycemic management in patients with T2DM.
      • Discuss clinical strategies to incorporate therapeutic classes and agents with insulin independent mechanisms of action into practice recommendations for the care of patients with T2DM.
      • Discuss new models of care in the management of T2DM which may assist providers in delivering improved patient care and educate patients on the importance of self-management of their disease.

      Responding to a Request for Educational Grant Application (REGA)
      Throughout the year, the Medical Grants department may announce a Request for Educational Grant Application (REGA). The intent of this announcement is to notify experienced and accredited Continuing Medical Education (CME) providers and accredited Continuing Education (CE) providers that BIPI/Lilly is interested in receiving applications for educational grants for support consideration.

      Grant applications in response to BIPI/Lilly Alliance REGAs need to be submitted online at https://bipisupport.envisionpharma.com/vt_bi. While REGAs may specify timing of requested responses, BIPI and Lilly will continue to review all grant requests which are received.

      To contact the BIPI/Lilly Alliance Medical Grants Department, please call (800) 295-0717. (8:00 a.m. - 5:00 p.m. EST, Monday – Friday)